01 December 2008
Point-of-care testing for interleukin-6 in cerebro spinal fluid (CSF) after subarachnoid haemorrhage
Julius DenglerBCDEF, Joerg C. SchefoldCDEF, Daniela GraetzBCD, Christian MeiselCDEFG, Gerald SplettstößerCDE, Hans-Dieter VolkCDEFG, Hans-Georg SchlosserABCDEFMed Sci Monit 2008; 14(12): BR265-268 :: ID: 869473
Abstract
Background
Intrathecal interleukin (IL)-6 is considered to be a proinflammatory biomarker for cerebral inflammatory response. This is of clinical importance for the prediction of vasospasm after subarachnoid haemorrhage (SAH). We evaluated a bedside technique for the quantitative measurement of IL-6 in the cerebrospinal fluid (CSF).
Material and Method
32 samples of CSF and serum were taken from 11 patients suffering from SAH on day 3, 4 and 5 after bleeding. A lateral flow immunoassay chip-test (POC-Test) was used for bedside testing and the results were compared to the standard chemiluminescence-based ELISA (Immulite) performed in a specialized laboratory.
Results
For CSF analysis Immulite and POC-Test show linear correlation (r2=0.81). The high IL-6 values found in SAH are depicted more easily by the POC-Test, because it has a working range of up to 10.000 pg/ml instead of up to 1000 pg/ml for Immulite. Serum IL-6 values were clearly lower, suggesting CNS inflammation in SAH.
Conclusions
The new chip-test provides a handy tool for the neurosurgical intensive care unit, analysing CSF IL-6 concentrations within 20 minutes. This is the first time a point-of care test for IL-6 in CSF was evaluated. The test results match the values achieved by the standard Immulite technique. Therefore a tool for clinical routine interleukin-6 investigation is provided which could find use in a broad variety of neurosurgical and neurological diseases.
Keywords: Subarachnoid Hemorrhage - cerebrospinal fluid, Point-of-Care Systems, Luminescence, Interleukin-6 - cerebrospinal fluid, Enzyme-Linked Immunosorbent Assay
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952